Skip to main content
SpringerLink
Log in

In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The biotransformation of midazolam is mediated by a cytochrome P-450 isozyme (P-450 IIIA) whose activity is highly variable. The kinetics of the 1′- and 4-hydroxylation of midazolam, the major routes of midazolam oxidation, by human liver microsomes have been examined to characterize further the cytochrome isozyme(s) catalysing these reactions, and to screen for drugs that might interfere with them.

In hepatic microsomal preparation from two kidney donors (extensive and poor metabolisers of debrisoquine) KM values for 1′-hydroxylation were 4.2 and 6.1 μM (extensive and poor metabolisers, respectively), and for the 4-hydroxylation they were 14.7 and 18.1 μM, respectively. The corresponding Vmax values were 25.8 and 29.8 and 17.0 and 18.1 nmolsdmg P−1·h−1. Both reactions appeared to be catalysed by the same or by coregulated isozymes.

Midazolam hydroxylations in vitro are inhibited by many drugs, including nifedipine and other dihydropyridine-type calcium channel blockers, ergot alkaloids, cyclosporine, erythromycin and phenothiazine-type neuroleptics.

A clinical case report illustrates the consequence of such a drug-drug interference with hepatic biotransformation; midazolam-induced sleep in a patient lasted for 6 days (t1/2=25 h).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith MT, Eadie MJ, O'Rourke T (1981) The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 19: 271–278

    Google Scholar 

  2. Dundee JW, Halliday NJ, Fee JPH (1984) Midazolam in intensive care. Br Med J 289: 1540

    Google Scholar 

  3. Heizmann P, Eckert M, Ziegler WH (1983) Pharmakokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16: 43S-49S

    Google Scholar 

  4. Byatt CM, Lewis LD, Dawling S, Cochrane GM (1984) Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in intensive car unit. Br Med J 289: 799–800

    Google Scholar 

  5. Byrne AJ, Yeoman PM, Mace P (1984) Accumulation of midazolam in patients receiving mechanical ventilation (letter). Br Med J 289: 1309

    Google Scholar 

  6. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI (1984) Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61: 27–37

    Google Scholar 

  7. Dundee JW, Collier PS, Carlisle RJT, Harper KW (1986) Prolonged midazolam elimination half-life. Br J Clin Pharmacol 21: 425–429

    Google Scholar 

  8. Maitre PO, Funk B, Crevoisier C, Ha HR (1989) Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol 37: 161–166

    Google Scholar 

  9. Kassai A, Toth G, Eichelbaum M, Klotz U (1988) No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet 15: 319–325

    Google Scholar 

  10. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molec Pharmacol 36: 89–96

    Google Scholar 

  11. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR (1989) The P450 superfamily: Updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8: 1–13

    Google Scholar 

  12. Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP (1986) Isolation and sequence determination of a cDNA clone related to cytochrome P-450 nifedipine oxidase. Proc Natl Acad Sci USA 83: 8064–8068

    Google Scholar 

  13. Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P450 of the human P450III gene family as the major cyclosporine metabolizing enzyme explains enteractions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635

    Google Scholar 

  14. Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytrochrome P-450. Molec Pharmacol 30: 287–295

    Google Scholar 

  15. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46: 521–527

    Google Scholar 

  16. Von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H (1980) Drug metabolism in human livers in vitro: Establishment of a human liver bank. Clin Pharmacol Ther 27: 711–725

    Google Scholar 

  17. Dayer P, Kronbach T, Eichelbaum M, Meyer UA (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation-characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 36: 4145–4152

    Google Scholar 

  18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin-phenol reagent. J Biol Chem 193: 265–275

    Google Scholar 

  19. Dayer P, Leemann T, Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor P-450DB1 activity. Clin Pharmacol Ther 45: 34–40

    Google Scholar 

  20. Sheiner LB (1983) ELSFIT (version 3.0) A program for extended least squares fit, UCSF, San Francisco, CA, USA

    Google Scholar 

  21. Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoisier C (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29: 272–277

    Google Scholar 

  22. Heizmann P, Ziegler WH (1981) Excretion and metabolism of 14C-midazolam in human following oral dosing. Arzneim Forsch (Drug Res) 31: 2220–2223

    Google Scholar 

  23. Klotz U, Mikus G, Zekorn C, Eichelbaum M (1986) Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 618–620

    Google Scholar 

  24. Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80

    Google Scholar 

  25. Leemann T, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739–741

    Google Scholar 

  26. Fabre G, Crevat-Pisano P, Dragna S, Covo J, Barra Y, Cano JP (1988) Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol 37: 1947–1953

    Google Scholar 

  27. Rodrigues AD, Gibson GG, Ioannides C, Parke DV (1987) Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins. Biochem Pharmacol 36: 4277–4281

    Google Scholar 

  28. Pasanen M, Taskinen T, Iscan M, Sotaniemi EA, Kairaluoma M, Pelkonen O (1988) Inhibition of human hepatic and placental xenobiotic monooxygenase by imidazole antimycotics. Biochem Pharmacol 37: 3861–3866

    Google Scholar 

  29. Back DJ, Stevenson P, Tjia JF (1989) Comparative effects of two antimycotic agents, ketoconazole and terfenadine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 28: 166–170

    Google Scholar 

  30. Thomson AH, Thomson GD, Hepburn M, Whiting B (1987) A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol 33: 435–436

    Google Scholar 

  31. Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM (1988) 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 35: 651–656

    Google Scholar 

  32. Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K (1989) Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 46: 43–50

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, University Hospital, Geneva, Switzerland

    M.-P. Gascon & P. Dayer

Authors
  1. M.-P. Gascon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Dayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gascon, MP., Dayer, P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41, 573–578 (1991). https://doi.org/10.1007/BF00314987

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00314987

Key words

Search

Navigation